Aoi Shunsuke, Baber Usman, Kovacic Jason C, Mehran Roxana, Aquino Melissa, Dangas George, Sweeny Joseph, Vijay Pooja, Shah Srushti, Barman Nitin, Moreno Pedro, Kini Annapoorna S, Sharma Samin K
Department of Cardiology, Mount Sinai Beth Israel, New York, New York.
The Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, New York.
Catheter Cardiovasc Interv. 2020 Sep 1;96(3):E278-E286. doi: 10.1002/ccd.28784. Epub 2020 Feb 22.
Our study investigated the impact of coronary artery calcification (CAC) and systemic inflammation on risks for major adverse cardiovascular events (MACE) following percutaneous coronary intervention (PCI).
CAC and systemic inflammation are known to be associated with an increased risk of cardiovascular events.
A total of 17,711 consecutive patients who underwent PCI in our hospital between January 1, 2009 and December 31, 2015 were categorized according to the degree of CAC (moderate/severe vs. none/mild) and high-sensitivity C-reactive protein (hsCRP) level (≥2 vs. <2 mg/L). MACE was defined as death, myocardial infarction (MI), or target vessel revascularization (TVR) occurring over 1 year.
Within the four groups, patients with both moderate/severe CAC and elevated hsCRP (n = 1,814 [10.2%]) were older with more comorbid risk factors compared to those with moderate/severe CAC alone (n = 1,687 [9.5%]), elevated hsCRP alone (n = 7,597 [42.9%]) or neither abnormality (n = 6,613 [37.3%]). The analogous 1-year MACE rates were 21.2, 14.9, 11.5, and 7.8%, respectively (p-trend < .001). Results were unchanged after multivariable adjustment, suggesting synergistic adverse effects in patients with both CAC and elevated hsCRP.
The presence of both moderate/severe CAC and systemic inflammation confers a synergistic effect on risk for MACE following PCI, indicating the need for novel or more intense therapeutic interventions to mitigate risk in such patients.
我们的研究调查了冠状动脉钙化(CAC)和全身炎症对经皮冠状动脉介入治疗(PCI)后主要不良心血管事件(MACE)风险的影响。
已知CAC和全身炎症与心血管事件风险增加有关。
对2009年1月1日至2015年12月31日期间在我院连续接受PCI的17711例患者,根据CAC程度(中度/重度与无/轻度)和高敏C反应蛋白(hsCRP)水平(≥2与<2 mg/L)进行分类。MACE定义为1年内发生的死亡、心肌梗死(MI)或靶血管血运重建(TVR)。
在四组中,与单独存在中度/重度CAC(n = 1687 [9.5%])、单独hsCRP升高(n = 7597 [42.9%])或无异常(n = 6613 [37.3%])的患者相比,同时存在中度/重度CAC和hsCRP升高的患者(n = 1814 [10.2%])年龄更大,合并的危险因素更多。类似的1年MACE发生率分别为21.2%、14.9%、11.5%和7.8%(p趋势<0.001)。多变量调整后结果不变,提示CAC和hsCRP升高的患者存在协同不良影响。
中度/重度CAC和全身炎症同时存在对PCI后MACE风险具有协同作用,表明需要新的或更强化的治疗干预措施来降低此类患者的风险。